On May 29th, 2013, GlaxoSmithKline (GSK) announced the acquisition of Okairos in an all-cash deal worth $325 million US. The Okairos acquisition helps complement the pharma giant’s existing vaccine technology and expertise and will enable GSK to continue its work developing the next generation of vaccines.
Montreal-based Caprion has established itself as a leader in the proteomic biomarker discovery field, using its proteomics discovery platform CellCarta® to develop pharmacodynamic biomarkers, disease markers and predictive biomarkers. OneMedRadio spoke with Caprion President and CEO Martin Leblanc about industry trends concerning increased risk factors, securing intellectual property and developing an in vitro diagnostics platform.
MicroRNA’s are very small endogenous, non-coding, oligonucleotides. They are implicated in regulating a broad range of biological processes. These are molecules which are involved in important regulation of biological processes, and the potential of using these molecules as targets for treatment is becoming ever more apparent. With increased interest from big pharma, it is now important to identify a handful of smallcap companies specializing in this field.
Investors and company executives may be “shocked” to learn that the chronic wound market size is estimated at $20 billion, according to AdvaMed.
Alpharetta, Ga.-based SanuWave (SNWV) looks to reduce that sticker shock. The company is developing potentially game-changing extracorp real shock wave technology for chronic wound care, cardiovascular, neurological and orthopedic conditions: its portfolio of shock wave therapies that sends ‘shockwaves’ through damaged cells, an action that stimulates the healing process.
In Part II of our interview with Vijay Aggarwal, Managing Partner of the Channel Group, we explore trends in the space, reimbursement issues, and the state of equity financing. Dr. Aggarwal also discusses changing investment strategy with regards to evaluating risk factors, a more sophisticated level of proof, and an evolving emphasis on the achieving and maintaining revenue during early financing rounds.
In case you missed it, Monday featured a number of interesting developments in the world of healthcare and life sciences. Most notably, a seemingly rare patent defeat may harm Novartis’ bottom line in India, but helps secure a mass population to a popular leukemia drug. India has emerged as a leading market for drug innovation, yet faces a crossroads — as legislation now protects what has become the largest generic drug market in the world. Additionally, we’re interested in some new developments in Chinese bird flu, sleep apnea, and sexual health in adolescents.
What if there was a way to substantially reduce high blood pressure for patients who have tried everything? Renal denervation is a hot topic, and ReCor Medical offers a unique ultrasound approach to enhance this exciting therapy…
OneMedRadio spoke with Clinova, a British pharmaceutical company focused on developing, manufacturing and marketing consumer healthcare products and medical device, has a rare global presence in multiple emerging markets, while also securing a significant market presence in Europe.
Young’s experience in both sectors makes him a unique voice in the osmosis of venture capital between mobile technology and life sciences. Young will participate in a panel dedicated to the subject at the 6th Annual OneMedForum in San Francisco, January 7-9. OneMedRadio spoke with Jack Young about investing in this sector, and the points of significant unmet medical need which represent the most promising opportunities.
OneMedPlace announced today that Peter Neupert of Health Evolution Partners and Jack Young of Qualcomm Ventures will participate in programming for the 6th Annual OneMedForum, January 7-9, 2013, in San Francisco. The two experts will take part in a panel dedicated to ‘Digital and Connected Health,’ an emerging sector with significant and diverse investment opportunities.
Copyright © 2024 | WordPress Theme by MH Themes